Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 19/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 12/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 8/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6471157 | 0.89 | OPRL1 (0.62) | OPRL1OPRM1OPRK1KCNH2OPRD1 | |
| SCHEMBL6472721 | 0.85 | OPRL1 (0.63) | OPRL1OPRM1OPRK1KCNH2OPRD1 | |
| SCHEMBL6471905 | 0.83 | OPRL1 (0.55) | OPRL1OPRM1KCNH2 | |
| SCHEMBL6471908 | 0.83 | OPRL1 (0.55) | OPRL1OPRM1KCNH2 | |
| SCHEMBL6472714 | 0.81 | OPRL1 (0.57) | OPRL1OPRM1OPRK1KCNH2OPRD1 | |
| SCHEMBL6472981 | 0.77 | OPRM1 (0.79) | OPRL1OPRM1KCNH2 | |
| SCHEMBL6471648 | 0.74 | OPRL1 (0.48) | OPRL1OPRM1OPRK1KCNH2 | |
| SCHEMBL6471651 | 0.74 | OPRL1 (0.48) | OPRL1OPRM1OPRK1KCNH2 | |
| SCHEMBL6504054 | 0.72 | OPRL1 (0.70) | OPRL1OPRM1KCNH2 | |
| SCHEMBL6501770 | 0.72 | OPRL1 (0.70) | OPRL1OPRM1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050153998-A1 | Tetrahydroisoquinoline or isochroman compounds | ITO FUMITAKA (JP) | 2005-07-14 | — | — | US | claimed |
| US-20050153998-A1 | Tetrahydroisoquinoline or isochroman compounds | ITO FUMITAKA (JP) | 2005-07-14 | — | — | US | disclosed |
| EP-1517895-A1 | 8-(BIARYL) QUINOLINE PDE4 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 2005-03-30 | — | — | EP | disclosed |
| WO-2005016913-A1 | TETRAHYDROISOQUINOLINE OR ISOCHROMAN COMPOUNDS AS ORL-1 RECEPTOR LIGANDS FOR THE TREATMENT OF PAIN AND CNS DISORDERS | PFIZER JAPAN, INC. (JP) | 2005-02-24 | — | — | WO | disclosed |
| WO-2004000814-A1 | 8-(BIARYL) QUINOLINE PDE4 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153998-A1 | Tetrahydroisoquinoline or isochroman compounds | OPRL1, NR1H3, HRH3 | OPRL1 1/4885OPRM1 8/4885OPRK1 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.